News | November 06, 2025
Teva reports 11th consecutive quarter of growth
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
ALS patients experience neuroinflammation and rapid neurodegeneration
Subscribe To Our Newsletter & Stay Updated
